Abstract:BackgroundWhen determining adjuvant treatment for endometrial cancer, the decision typically relies on factors such as cancer stage, histologic grade, subtype, and a few histopathologic markers. The Cancer Genome Atlas revealed molecular subtyping of endometrial cancer, which can provide more accurate prognostic information and guide personalized treatment plans. ObjectiveTo summarize the expression and molecular basis of the main biomarkers of endometrial cancer. Search StrategyPubMed was searched from January 2000 to March 2023. Selection CriteriaStudies evaluating molecular subtypes of endometrial cancer and implications for adjuvant treatment strategies. Data Collection and AnalysisThree authors independently performed a comprehensive literature search, collected and extracted data, and assessed the methodological quality of the included studies. Main ResultsWe summarized the molecular subtyping of endometrial cancer, including mismatch repair deficient, high microsatellite instability, polymerase epsilon (POLE) exonuclease domain mutated, TP53 gene mutation, and non-specific molecular spectrum. We also summarized planned and ongoing clinical trials and common therapy methods in endometrial cancer. POLE mutated endometrial cancer consistently exhibits favorable patient outcomes, regardless of adjuvant therapy. Genomic similarities between p53 abnormality endometrial cancer and high-grade serous ovarian cancer suggested possible overlapping treatment strategies. High levels of immune checkpoint molecules, such as programmed cell death 1 and programmed cell death 1 ligand 1 can counterbalance mismatch repair deficient endometrial cancer immune phenotype. Hormonal treatment is an appealing option for high-risk non-specific molecular spectrum endometrial cancers, which are typically endometrioid and hormone receptor positive. Combining clinical and pathologic characteristics to guide treatment decisions for patients, including concurrent radiochemotherapy, chemotherapy, inhibitor therapy, endocrine therapy, and immunotherapy, might improve the management of endometrial cancer and provide more effective treatment options for patients. ConclusionsWe have characterized the molecular subtypes of endometrial cancer and discuss their value in terms of a patient-tailored therapy in order to prevent significant under- or overtreatment.

Molecular Classification Guides for the Postoperative Adjuvant Therapy of Early-Stage Endometrial Carcinoma

The Influence of Molecular Classification in the Selection of Postoperative Adjuvant Therapy in Endometrial Carcinoma

Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies

Comparison of Molecular and Clinicopathologic-Based Classifications and the Transition of Adjuvant Treatment Mode for Early-Stage Endometrial Cancer.

Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy

Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer

Molecular classification of endometrial carcinoma: a clinically oriented review

Molecular characterization of endometrial cancer and therapeutic implications

Endometrial Cancer: An Update on Prognostic Pathologic Features and Clinically Relevant Biomarkers

Incorporating Molecular Classification When Stratifying the Survival Risk of Patients with High-Grade Endometrial Carcinomas

A Timely Update of Immunohistochemistry and Molecular Classification in the Diagnosis and Risk Assessment of Endometrial Carcinomas

Adjuvant Therapy for High-risk Endometrial Carcinoma

Update in the molecular classification of endometrial carcinoma

Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection

[Clinical application of TCGA molecular classification in endometrial endometrioid carcinoma]

Application of molecular classification to guiding fertility-sparing therapy for patients with endometrial cancer or endometrial intraepithelial neoplasia

Research on the Guiding Effect of CTCs on Postoperative Adjuvant Therapy for Patients with Early Stage Endometrial Cancer

Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment

Molecular classification in fertility-sparing treatment of early-stage endometrial cancer: A potential tool for optimizing patient selection

Tumor Molecular Features Predict Endometrial Cancer Patients' Survival after Open or Minimally Invasive Surgeries.

Molecular classification of endometrial cancer and its association with PD-1/PD-L1 blockade